

Correction: γ Klotho is a novel marker and cell survival factor in a subset of triple negative breast cancers

Nuša Trošt^{1,2}, Samuel Peña-Llopis², Sajjan Koirala³, Jurij Stojan¹, Patrick Ryan Potts³, Klementina Fon Tacer³ and Elisabeth D. Martinez^{2,4}

¹ Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

² Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

³ Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

⁴ Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Correspondence to: Elisabeth D. Martinez, e-mail: elisabeth.martinez@utsouthwestern.edu

Correspondence to: Klementina Fon Tacer, e-mail: klementina.fontacer@utsouthwestern.edu

Keywords: LCTL; gamma Klotho; FGF; breast cancer; cancer therapy; ROS; oxidative stress; oncogene

Published: January 25, 2019

Copyright: Trošt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The correct Keywords are given below:

Keywords: LCTL; gamma Klotho; FGF; breast cancer; cancer therapy; ROS; oxidative stress; oncogene

Original article: Oncotarget. 2016; 7:2611-2628. <https://doi.org/10.18632/oncotarget.6006>